APPBP2 Antibody

Code CSB-PA227449
Size US$166
Order now
Image
  • The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA227449(APPBP2 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)
  • The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using CSB-PA227449(APPBP2 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
APPBP2
Alternative Names
amyloid beta precursor protein (cytoplasmic tail) binding protein 2 antibody; Amyloid beta precursor protein-binding protein 2 antibody; Amyloid protein binding protein 2 antibody; Amyloid protein-binding protein 2 antibody; APBP2_HUMAN antibody; APP BP2 antibody; APP-BP2 antibody; Appbp2 antibody; PAT1 antibody; Protein interacting with APP tail 1 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Fusion protein of Human APPBP2
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:2000-1:5000
IHC 1:25-1:100
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation. The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms. The CRL2(APPBP2) complex specifically recognizes proteins with a -Arg-Xaa-Xaa-Gly degron at the C-terminus, leading to their ubiquitination and degradation. The CRL2(APPBP2) complex mediates ubiquitination and degradation of truncated SELENOV selenoproteins produced by failed UGA/Sec decoding, which end with a -Arg-Xaa-Xaa-Gly degron. May play a role in intracellular protein transport: may be involved in the translocation of APP along microtubules toward the cell surface.
Gene References into Functions
  1. It facilitates the regulator of calcineurin 1-mediated apoptosis by downregulating proteasome subunits. PMID: 25194880
  2. Association of the herpes simplex virus type 1 Us11 gene product with the cellular kinesin light-chain-related protein PAT1 results in the redistribution of both polypeptides. PMID: 12915535
Subcellular Location
Nucleus. Cytoplasm, cytoskeleton. Membrane; Peripheral membrane protein.
Database Links

HGNC: 622

OMIM: 605324

KEGG: hsa:10513

STRING: 9606.ENSP00000083182

UniGene: Hs.84084

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*